sb2

SB273005 is an orally active and potent nonpeptide integrin αvβ3 antagonist that inhibits αvβ3 and αvβ5 and reduces the production of Th2 cells and the cytokine IL-10 in pregnant mice.

SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.

SB24011, a STING-TRIM29 interaction inhibitor, has an IC₅₀ value of 3.85 μM. It boosts STING immunity by upregulating STING protein levels, thereby enhancing the immunotherapeutic effects of STING agonists and anti-PD-1 antibodies through systemic anticancer immunity [1].

Compound CP2, also known as SPSB2-iNOS inhibitory cyclic peptide-2, serves as an inhibitor disrupting the interaction between SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS. It binds to the SPSB2 on the iNOS site with an affinity (K D) of 21 nM. This peptide is characterized by its resistance to reduction and oxidative stability [1].

SB228357 is a potent and selective antagonist of the 5-HT receptor with pKis of 6.9, 8.0, and 9.0 for 5-HT2A, 5-HT2B, and 5-HT2C, respectively.

SB234551 is a selective antagonist of endothelin ETA receptor.

SPSB2-iNOS inhibitory cyclic peptide-1, an inhibitor for the interaction between the SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, binds SPSB2 at the iNOS site with a K D of 4.4 nM. It is resistant to proteases pepsin, trypsin, and α-chymotrypsin and remains stable in human plasma and oxidative environments [1].

SB26019 is a potent anti-neuroinflammatory compound that modulates the activation of NF-κB by promoting the formation of monomeric α-tubulin, thereby hindering the translocation of p65 and regulating neuroinflammatory processes [1].

SB2602 selectively inhibits mTOR.

**SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3)** is an inhibitor that disrupts the interaction between SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, by binding to SPSB2 at the iNOS site with a K D of 7 nM [1].

SB269652 is the pioneering drug-like allosteric modulator of the dopamine D2 receptor.

SB236057 is a potent and selective inverse agonist for the 5-HT receptor, acting especially at 5-HT autoreceptors on nerve terminals. It produces a rapid increase in 5-HT levels in the brain. SB236057 also acts as a potent teratogen, producing severe musc

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC50 of 200 nM.

SB251023 is an agonist of β3-adrenoceptor.

SB220025 is an orally available, selective and potent inhibitor of P38 mitogen-activated protein kinase that inhibits p56Lck and PKC, inhibits endothelial growth hormone-induced Ca(2+) signaling, and inhibits angiogenesis, and can be used in the study of arthritis.

ASB20123, a CNP ghrelin chimeric peptide, promotes bone growth and has potential research applications in growth disorders and dwarfism [1].

SB297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ. It is at least 250-fold selective for CCR3 over a panel of other chemokine receptors. SB 297006 blocks CCR3-mediated calcium mobilization induced by eotaxin, eotaxin-2, and MCP-4 in transfected cells. It suppresses antigen-induced accumulation of Th2 lymphocytes and eosinophils in lungs of mice when delivered subcutaneously (100 mg kg).

CAY10526 (BTH) is a selective mPGES-1 inhibitor that acts as an inhibitor of the NF-κB signaling pathway.